# TB-500 and measured healing

> TB-500 findings · Peptide Therapy Evidence Review — TB-500 in Peptide Therapy Evidence Review: full thymosin beta-4 wound coverage, mouse heart function, rat movement and fragment uncertainty.

Skin coverage, a working heart and a movement test measure different changes. Most of the cited experiments gave full thymosin beta-4.

## New skin and smaller wounds

In a [rat full-thickness wound experiment](https://pubmed.ncbi.nlm.nih.gov/10469335/), thymosin beta-4 increased new skin coverage by 42% at four days and up to 61% at seven days versus saline. Wounds also contracted more, with increased collagen deposition and vessel growth.

Coverage and contraction deserve separate words. New skin growing across a wound and a wound drawing together are different contributions to closure. I appreciate the wound paper’s separate measurements: each describes a different contribution to closure. A single attractive image would leave more of the repair process undescribed.

The material given to the rats was full thymosin beta-4. The paper leaves human healing with the short TB-500 fragment unanswered.

![A technician places a tissue slide on a light microscope beside a slide tray](images/wound-slide-bench.webp)

*A constructed editorial scene of tissue examination. Microscopy can document repair features; this scene shows no actual tissue or result from the rat study.*

## The molecule in the experiment

TB-500 is the synthetic Ac-LKKTETQ fragment: seven amino acids corresponding to positions 17–23 of the 43-amino-acid thymosin beta-4 protein. The fragment contains the protein's actin-binding region.

The [structural work on thymosin beta-4 and actin](https://pubmed.ncbi.nlm.nih.gov/15329672/) shows how the larger protein holds individual actin units apart, regulating the material available for cells to change shape and move. A [review of the larger protein’s repair biology](https://pubmed.ncbi.nlm.nih.gov/22074294/) connects that activity with cell migration, vessel growth and reduced scar-forming cells across experimental models.

The short fragment carries a biologically interesting sequence. Matching human effects require evidence for that fragment. The mechanism convinces me of a cellular role; the fragment's clinical result is still missing.

## Heart function and movement after stroke

The outcomes sometimes go beyond tissue appearance. In [mice with experimental heart injury](https://pubmed.ncbi.nlm.nih.gov/15565145/), full thymosin beta-4 promoted cardiac and endothelial cell migration, enhanced early heart-cell survival and improved cardiac function. Researchers traced a protein complex involving PINCH and integrin-linked kinase, followed by activation of the survival signal Akt.

In a separate [rat stroke dose-response experiment](https://pubmed.ncbi.nlm.nih.gov/25060418/), full thymosin beta-4 improved neurological function at two of the amounts tested. The highest amount gave no significant benefit. Differences appeared from day fourteen through day fifty-six.

I read the uneven response as a challenge to an easy story about ever-increasing benefit. These were experimental stroke outcomes in rats, alongside a different cardiac experiment in mice. They supply questions for further work with the actual molecule and injury under discussion.

## Safety observations with full thymosin beta-4

The [placebo-controlled safety study in 40 healthy volunteers](https://pubmed.ncbi.nlm.nih.gov/20536472/) gave full thymosin beta-4 intravenously. Infrequent mild or moderate adverse events were reported, with no serious adverse events or dose-limiting toxicity. This was a brief safety study in healthy people, using the full protein.

Accounts of TB-500 use describe less stiffness, soreness and easier movement; other accounts mention local redness or aching, tiredness, headaches, dizziness, flu-like feelings and nausea. These are anecdotes, not clinical evidence, and they cannot establish the fragment's safety or the cause of a reported improvement.

TB-500 has no approval for human use and is prohibited in sport. Controlled human trials have not established the fragment's injury benefits or long-term safety. The [musculoskeletal peptide review](https://pubmed.ncbi.nlm.nih.gov/41966639/) gives the animal findings their place while stressing the scarcity of rigorous human safety data. Concerns about unwanted vessel growth and cell migration remain theoretical for TB-500 in people.

---

An independent evidence desk for repair-peptide studies, keeping every tissue claim beside its comparator and outside the bounds of medical advice.